Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

394

HTML

3681

Figures (1-1)

229

Tables (1-2)

214

Sum=4518

Jun 7, 2006 (publication date) through Nov 12, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jun 7, 2006; 12(21): 3297-3305
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3297

Table 1 FDA-licensed tyrosine kinase inhibitors, their targets, modes of action, and clinical use

Agent	Target	Mode of action	Established clinicalapplication
Imatinib mesylate	bcr-abl; PDGFR, c-kit	Kinase inhibitor	CML, GIST, hypereosinophilic syndrome
Gefitinib	erbB1/EGFR	Kinase inhibitor	NSCLC
Erlotinib	erbB1/EGFR	Kinase inhibitor	NSCLC
Cetuximab	erbB1/EGFR	Blocking antibody	Colorectal cancer
Trastuzumab	erbB2/HER	Blocking antibody	Breast cancer
Bevacizumab	VEGF	Neutralizing antibody	Colorectal cancer

Citation: Becker J, Müller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World J Gastroenterol 2006; 12(21): 3297-3305
URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3297.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3297